Phthalide Compound Use for Purkinje Cell Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are ineffective for diseases related to the degeneration of Purkinje cells, which are associated with neuronal disorders such as Alzheimer's disease and spinal cerebellar atrophy, leading to movement coordination disorders and cell death.
Innovation Solution
The use of n-butylidenephthalide (BP) or its metabolic precursors, pharmaceutically acceptable salts, and esters as a medicament to treat and delay the degeneration of Purkinje cells, potentially delaying the onset of spinocerebellar atrophy by preventing cell death and increasing ubiquitination of proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If physical therapy and respiratory care are provided to patients with Purkinje cell degeneration, then complications can be reduced and disease progression can be slowed, but the treatment remains ineffective in preventing cell death or reversing degeneration
Solution Approach 1:
The patent introduces phthalide compounds as intermediary substances that mediate between the existing physical therapy approach and the desired protective effect on Purkinje cells. These compounds act as biochemical mediators that enhance cell survival signals and reduce apoptosis, bridging the gap between supportive care and active disease modification.
Solution Approach 2:
The patent applies parameter changes by introducing pharmacological agents that alter key biochemical parameters within Purkinje cells, such as mitochondrial function, oxidative stress levels, and apoptosis pathway activation. This transforms the treatment from purely mechanical/physical support to a approach that modifies cellular physiological parameters.
2Ease of operation
If no specific medicament is available for Purkinje cell degeneration, then patients can receive supportive care, but effective treatment for the underlying degeneration process cannot be provided
Solution Approach 1:
The patent segments the complex neurodegenerative process into specific molecular pathways and targets them with phthalide compounds. By focusing on specific mechanisms such as mitochondrial protection and anti-apoptotic pathways, the treatment addresses the degeneration process in discrete, manageable targets rather than requiring a comprehensive solution for the entire disease process.
Solution Approach 2:
Phthalide compounds serve as intermediary agents that translate the concept of supportive care into active disease modification. These compounds mediate between the patient's existing physiological systems and the desired protective outcome, providing a bridge between available supportive care and effective disease-modifying treatment.
3Adaptability or versatility
If abnormal CAG repeat sequences in ATXN3 gene are present, then spinocerebellar atrophy can be classified into various subtypes, but no effective treatment exists for any subtype
Solution Approach 1:
The patent applies universality by developing phthalide compounds that provide a common protective mechanism against Purkinje cell degeneration across different spinocerebellar atrophy subtypes. Rather than creating subtype-specific treatments, the compounds act through universal cellular protection mechanisms that are effective regardless of the specific genetic mutation or disease classification.
Solution Approach 2:
The patent uses parameter changes to address diverse disease subtypes by modifying key cellular parameters such as mitochondrial membrane potential, oxidative stress, and apoptosis resistance. These parameter modifications create a universal protective effect that transcends the specific genetic or molecular characteristics of different SCA subtypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BP effectively delays and prevents Purkinje cell death, improves motor behavior, and increases ubiquitination in cerebellar tissues, thereby slowing the progression of spinocerebellar atrophy, particularly type 3, as demonstrated in zebrafish and mouse models.
Implementation Method 1
The results indicate that BP and its metabolites can be converted into each other in living bodies and have in common the ability to activate adenosine A1 receptors and inhibit the death of Purkinje cells
Implementation Method 2
ATXN3 is a deubiquitinating enzyme (DUB). In the ubiquitin-proteasome pathway, ATXN3 plays a role in preventing abnormal protein aggregation
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
Disclosed is a use of phthalide compound for the preparation of a medicament. The medicament is especially used for treating and/or delaying the degeneration of Purkinje cells, and the phthalide compound is selected from the following group: butylidene phthalide, a metabolic precursor of butylidene phthalide, a pharmaceutically acceptable salt of the metabolic precursor of butylidene phthalide, a pharmaceutically acceptable ester of the metabolic precursor of butylidene phthalide, and any combination of the foregoing.